Welcome to our dedicated page for Bioforce Nanosciences Hldgs In SEC filings (Ticker: BFNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bioforce Nanosciences Hldgs In's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bioforce Nanosciences Hldgs In's regulatory disclosures and financial reporting.
BioForce Nanosciences Holdings, Inc. (BFNH) reported a very small balance sheet at September 30, 2025, with $784 in cash and total assets and $500,722 in total liabilities, resulting in a stockholders’ deficit of $499,938. The company generated no revenue for the three- and nine-month periods ended September 30, 2025 or 2024, reflecting no unit sales of its BioForce Eclipse supplement.
For the nine months ended September 30, 2025, BioForce recorded a net loss of $1,173,346, compared with a loss of $367,277 a year earlier, driven largely by a $801,193 loss on liability settlement from issuing 4,250,000 shares to satisfy $2,173,000 of amounts owed to a director. The accumulated deficit reached $162,293,512, and the company discloses substantial doubt about its ability to continue as a going concern, relying on related-party loans, including a $10,000 cash infusion in November 2025, and acknowledging material weaknesses in internal control over financial reporting.